# CJC-1295 FAQ: Safety, Status, and the Common Questions > CJC-1295 FAQ: is it FDA approved, is it a steroid, what are the side effects, does it affect testosterone. Direct, sourced answers from the published GHRH-analog record. Twenty-two of the most-asked CJC-1295 questions — safety, regulatory status, the DAC/no-DAC split, the ipamorelin pairing — each answered directly and cited where the answer carries a number. ## Reported and Theoretical Concerns The CJC-1295 side effects question maps to one mechanism: sustained elevation of GH and IGF-1, and what is known and unknown about its consequences. CJC-1295 is not approved for human use, and the human evidence base is limited to early-phase pharmacokinetic studies, so most concerns are theoretical or drawn from the broader GH-axis literature rather than from long-term CJC-1295 trials [1][14]. The recurring flags are these. GH-axis stimulation can cause fluid retention, edema and effects on insulin sensitivity. Epidemiology links higher IGF-1 to a modestly increased risk of certain cancers, which raises a theoretical question about any intervention that elevates IGF-1 for days at a time. FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity and other safety concerns for GH secretagogues including CJC-1295. The original long-acting DAC development program (ConjuChem) was discontinued, and a patient death during the development era is frequently cited in connection with the halted phase 2 trial, though a causal link to CJC-1295 was not established in the public record [14]. ### Is CJC-1295 safe? CJC-1295 is not approved for human use and human data are limited to early PK studies; sustained GH/IGF-1 elevation raises theoretical concerns — fluid retention, IGF-1/cancer epidemiology, immunogenicity — and the original DAC program was discontinued [1][14]. Safety in healthy adults is not established. ### Are CJC-1295 peptides safe? Safety in humans is not established; the peer-reviewed evidence base in healthy adults is thin and short-term, and FDA briefing materials flagged immunogenicity and other concerns [14]. The molecule's hormonal effects are documented; its long-term safety is not. ### What side effects are reported or theorized? Reported and theoretical concerns from GH-axis stimulation include fluid retention/edema, effects on insulin sensitivity, and — from epidemiology — questions about sustained IGF-1 elevation and cancer risk; FDA also cited immunogenicity [14]. There is no long-term CJC-1295 safety trial in healthy adults to quantify these. ### What are the side effects of CJC-1295? The side effects discussed in the literature follow from raising GH and IGF-1: fluid retention and edema, possible effects on insulin sensitivity, and the theoretical IGF-1/cancer-risk question from epidemiology, alongside FDA-cited immunogenicity [14]. These are mechanism-derived and epidemiological concerns, not a catalogue from controlled CJC-1295 trials. ## Status, classification and comparisons ### Is CJC-1295 FDA approved? No. CJC-1295 is an unapproved research chemical with no approved human indication anywhere; the 2024 FDA Pharmacy Compounding Advisory Committee did not recommend it for the 503A compounding bulks list [6]. It is sold and handled as a research chemical, not a medicine. ### Is CJC-1295 a steroid? No. CJC-1295 is a peptide GHRH analog that acts on the GHRH receptor to stimulate the body's own growth hormone; it is not an anabolic steroid [7]. It works on the GH/IGF-1 axis, a separate system from the androgen pathway. ### Does CJC affect testosterone? CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis; the published CJC-1295 literature does not establish a direct effect on testosterone [1]. Its documented targets are the GHRH receptor and the downstream GH/IGF-1 cascade. ### Does CJC-1295 lower testosterone? The published CJC-1295 literature does not document a testosterone-lowering effect; its target is the GHRH receptor and the GH/IGF-1 axis [1]. No controlled study attributes a change in testosterone to it. ### Are peptides safer than TRT? There is no head-to-head evidence supporting a safety comparison; CJC-1295 is unapproved with limited human data, whereas testosterone therapy is a regulated, separately studied intervention [14]. The two act on different axes and are not interchangeable. ## Mechanism, identity and dosing questions ### What is CJC-1295? A synthetic long-acting analog of growth-hormone-releasing hormone, built on hGRF(1-29) with four protease-resistant substitutions; the DAC variant adds covalent albumin binding for a multi-day half-life [1][9]. The no-DAC form keeps the substitutions but is short-acting. ### What does CJC-1295 do? In published studies it raises growth hormone and downstream IGF-1 in a dose-dependent, sustained way by stimulating the GHRH receptor on the pituitary [1]. A single DAC dose elevated both hormones for days in healthy adults. ### How does CJC-1295 work at the molecular level? It binds the GHRH receptor (a class B GPCR) on pituitary somatotrophs, activating Gs/cAMP/PKA signaling that drives CREB-mediated GH transcription and pulsatile GH release, which raises hepatic IGF-1 [7][8]. The four substitutions and the DAC albumin bond give it duration. ### What is CJC-1295 DAC? The variant whose C-terminal lysine is functionalized with a maleimidopropionyl linker that covalently bonds to serum albumin (Cys34), extending plasma half-life toward that of albumin itself — estimated at 5.8 to 8.1 days [1][2]. The full form comparison is on [CJC-1295 DAC vs no-DAC](/dac-vs-no-dac). ### How much CJC-1295 should I take? Human PK studies used single subcutaneous doses of 30, 60 or 90 ug/kg; community protocols (100-300 ug fixed) are not derived from controlled human trials, and no human dosing is recommended here [1][3]. The research-dose record is on [doses used in research](/dosage). ### How much CJC-1295 DAC should I take? Healthy-adult PK studies of the DAC form used 30 or 60 ug/kg subcutaneously; the multi-day half-life is why a single dose elevates GH/IGF-1 for days [1]. These are research doses, not a human protocol. ### What to expect when taking CJC-1295? In studies, the measurable effects were biochemical — dose-dependent, multi-day rises in GH and IGF-1 — rather than validated clinical outcomes in healthy adults [1][3]. This describes research observations, not expected personal results. ## Pulsatility, the ipamorelin pairing, and handling ### Does CJC-1295 preserve the natural pulse pattern of growth hormone? Yes. In healthy men, a single 60-90 ug/kg dose raised basal GH about 7.5-fold and IGF-1 about 45% a week later while the frequency and magnitude of pulsatile GH secretion stayed unchanged [3]. The analog raised the floor the pituitary pulsed from without flattening its rhythm. ### What is CJC-1295 ipamorelin? A commonly discussed research pairing of a GHRH analog (CJC-1295) with a selective growth-hormone secretagogue (ipamorelin) that releases GH with minimal ACTH/cortisol or prolactin effect. The two act on different receptors, which is the rationale for pairing them; the mechanism is covered on the [GH and IGF-1 research](/research) page. ### Does CJC-1295 and ipamorelin work? GHRH and GHRP-class peptides act through distinct receptors and synergize — co-administration produces supra-additive GH release — but controlled human efficacy data specifically for the CJC-1295/ipamorelin pairing are limited [12]. The general synergy is established pharmacology; a trial validating the specific combination is not. ### How much CJC-1295 / ipamorelin should I take? Controlled human dosing for the combination is not established; forum protocols are not trial-derived. The research rationale for pairing is two-receptor synergy (a GHRH analog plus a selective GHRP), not a validated dose [12]. No human dosing is recommended here. ### How to reconstitute CJC-1295? In research handling the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible because it is a peptide [1]. This describes laboratory handling, not human-use instructions; the [doses used in research](/dosage) page covers routes and stability. --- An emerald-on-black console reading of the CJC-1295 record — the four substitutions, the DAC albumin handle, and the multi-day-versus-short-acting half-life each logged to its study and split by form, with no clinic behind the panel and nothing here dispensed or sold.